ArticleSignal transduction and targeted therapy2022

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.

Qi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.